Fortitude Family Office’s Esperion Therapeutics ESPR Stock Holding History

Fortitude Family Office’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-243	Closed	-$768	–	2677
2026 Q2	$768	Hold	243	–	–	﹤0.01%	1846
2026 Q1	$666	Buy	+243	New	+$769	﹤0.01%	1622

Fortitude Family Office's ESPR Position: Q3 2026 in Review

Fortitude Family Office sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 243 shares — an estimated $768 sold.

Fortitude Family Office first reported a position in ESPR in Q1 2026 and held it in 2 quarters. The position peaked at $768 in Q2 2026. 0 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.

Fortitude Family Office reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
Fortitude Family Office sold 243 Esperion Therapeutics shares in Q3 2026, an estimated $768.
Fortitude Family Office first reported a position in Esperion Therapeutics in Q1 2026 and held it in 2 quarters.
Fortitude Family Office's Esperion Therapeutics position peaked at $768 in Q2 2026.
0 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.